ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2031-Randwick-Scientia-Clinical-Research-Ltd
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
44
trial(s) found.
NCT07772934
Advanced
Phase 1 / Phase 2
Not yet recruiting
Phase 1/2a Open-label Clinical Trial Evaluating VBC117, an EGFR and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors (
VBC117-01-01
)
bispecific-EGFR/CDH17 antibody-drug conjugate
oncolytic herpes simplex virus
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT07710885
Advanced
Phase 3
Recruiting
A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers (
FOENIX-BTC
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
antimetabolite
pan-FGFR inhibitor,irreversible
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT07686445
Advanced
Phase 1
Not yet recruiting
A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN4035 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations and Enriched for CEACAM5 Expression (
AN4035S0101
)
anti-CEACAM5 antibody-drug conjugate,pan-RAS inhibitor,tricomplex inhibitor-payload
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
WA
6009 - Nedlands - Linear Clinical Research
NCT07545356
Advanced
Phase 1
Not yet recruiting
A Phase 1 Dose-Finding and Dose Optimization-Expansion Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors (
KIVU-305-01
)
anti-CEACAM5 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2500 - Wollongong - Wollongong Hospital
QLD
4999 - Unspecified - Clinical Trial Site QLD
NCT07475559
Advanced
Phase 1
Not yet recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Anti-tumor Activity of JSKN016HC in Subjects With Advanced Malignant Solid Tumors (
JSKN016HC-101
)
bispecific ERBB3/TROP2 antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT07456046
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation (
D3S-003-100
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07455734
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors (
BNT3214-01
)
unknown drug class
Cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
NCT07362888
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors (
ADCE-B05-001
)
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07334119
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors (
MTX-HER2-304
)
CAR-NK/myeloid-cell therapy,ERBB2-targeting
HER2-expressing solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NCT07300943
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of CLIO-8221 in Patients With Advanced Solid Tumors (
CLIO-8221-001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase/ATR inhibitor-payload
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07263594
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1324 in Participants With Advanced/Metastatic Gastrointestinal Tumors (
DB-1324-101
)
anti-CDH17 antibody-drug conjugate
Gastrointestinal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07244705
Advanced
Phase 1 / Phase 2
Recruiting
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC) (
ABT-301-103
)
HDAC inhibitor
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal adenocarcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT07229313
Advanced
Phase 1
Recruiting
A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (
KIVU-107-01
)
anti-PTK7 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4999 - Unspecified - Clinical Trial Site QLD
SA
5999 - Unspecified - Clinical Trial Site WA
NCT07172919
Advanced
Phase 2
Recruiting
A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor,OFF-state inhibitor
anti-EGFR monoclonal antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT07147348
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (
BNT3212-01
)
bispecific EGFR/ERBB3 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT07141706
Advanced
Phase 1
Recruiting
A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors (
DB-1317-101
)
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07042100
Advanced
Phase 1
Recruiting
A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors (
SBO-154-25-01
)
anti-MUC1 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06974110
Advanced
Phase 1
Recruiting
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors (
MOMA-341-001
)
WRN inhibitor
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06929663
Advanced
Phase 1
Recruiting
A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 for Injection, an Anti-Trop2/Nectin4 Bispecific Antibody-drug Conjugate, in Patients With Advanced Solid Tumors (
AK146D1-102
)
bispecific Trop2/Nectin4 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT06788509
Haem
Phase 1
Enrolling by invitation
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring (
PLATFORMPACAN1001
)
BTK inhibitor
Ibrutinib
JNJ-80948543
MALT1 inhibitor
Rezetamig
Safimaltib
bispecific T-cell engager,CD22-targeting
cancer therapy
cancer therapy,BTK-targeting
cancer therapy,CD20-targeting
cancer therapy,CD22-targeting
cancer therapy,CD79b-targeting
cancer therapy,MALT1-targeting
immuno-oncology therapy,CD20-targeting
immuno-oncology therapy,CD22-targeting
immuno-oncology therapy,CD79b-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
trispecific CD79b/CD20/CD3 antibody
Cancer
Castrate-resistant prostate cancer
Leukaemia
Lymphoma
Myelodysplastic syndrome
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06751329
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors (
DM002001
)
bispecific-ERBB3/MUC1 antibody-drug conjugate
Colorectal adenocarcinoma
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2500 - Wollongong - Cancer Care Wollongong
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06750185
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors (
BNT317-01
)
cancer therapy,undisclosed mechanism
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
NCT06741644
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors (
CS2009-101
)
trispecific PD-1/VEGFA/CTLA4 antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06736704
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors (
SNV4818-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
Breast cancer
Endometrial cancer
HPV-related cancer
Ovarian cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06707610
Advanced
Phase 1
Recruiting
A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors (
ALK202-01
)
anti-EGFR/cMET antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
NCT06634849
Advanced
Phase 1 / Phase 2
Recruiting
A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. (
PTT-4256-01
)
GPR65 inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
Breast cancer
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06597721
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors (
ADCE-T02-001
)
anti-TF antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06554795
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors (
DB-1419-O-1001
)
bispecific B7H3/PD-L1 antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06400485
Advanced
Phase 1
Recruiting
First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors (
AMT-676-01
)
anti-CDH17 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06326411
Advanced
Phase 1
Recruiting
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue
NST-628
Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
pan-RAF/MEK glue
Glioma
Melanoma
NOT Melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06253130
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors (
EIK1003-001
)
PARP1-selective inhibitor
Breast cancer
Endometrial cancer
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast Private Hospital
NCT06220864
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors (
SNV1521-101
)
PARP1-selective inhibitor
Prostate cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06063681
Advanced
Phase 1
Recruiting
Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors (
StingrayTx
)
ENPP1 inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
NCT05969041
Advanced
Phase 1
Recruiting
MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (
MYE-Symphony
)
Trop2-targeting lipid-nanoparticles
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05785754
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (
DCSZ11-101
)
anti-CD93 monoclonal antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2076 - Wahroonga - Sydney Adventist Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
4812 - Townsville - Townsville University Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05636215
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI354A101
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Biliary tract cancer
Breast cancer
Colorectal cancer
Gastric cancer
Gynaecological cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
Clear cell renal cell carcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
NA
NA
NCT05356741
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (
VIR-5818-V101
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,ERBB2-targeting
HER2-expressing solid tumour
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05277168
Advanced
Phase 1 / Phase 2
Recruiting
AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS (
SHR-A1904-I-104
)
anti-CLDN18.2 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Sydney South West Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Gold Coast Private Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05150691
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors (
DB-1303-O-1001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
HER2-positive solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05142189
Advanced
Phase 1
Recruiting
LuCa-MERIT-1
: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
vaccine therapy,MAGE-A3/CLDN6/KK-LC-1/PRAME/MAGE-A4/MAGE-C1-targeting
Non-small cell lung cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Cancer Research SA
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (39)
Not yet recruiting (4)
Enrolling by invitation (1)
Recruitment Country and State
NSW (44)
VIC (29)
QLD (21)
WA (20)
SA (15)
Phase
Phase 1 (24)
Phase 1 / Phase 2 (18)
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (43)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
25%
PD-1
20%
ERBB2
14%
PD-L1
7%
EGFR
7%
ERBB3
5%
Trop2
5%
KRAS
5%
CDH17
5%
VEGF
5%
VEGFA
5%
CTLA4
5%
CDK4
5%
CDK6
5%
ER
5%
PI3Kalpha
5%
oestrogen axis
5%
MET
5%
B7H3
5%
PARP
5%
PARP1-selective
5%
AR
5%
CYP17A1
5%
androgen axis
5%
SMO
5%
FGFR
2%
FGFR1
2%
FGFR1/2/3
2%
FGFR2
2%
FGFR3
2%
FGFR4
2%
CEACAM5
2%
ATR
2%
HDAC
2%
PTK7
2%
HRAS G12C
2%
NRAS G12C
2%
MUC1
2%
WRN
2%
Nectin4
2%
BTK
2%
CD20
2%
CD22
2%
CD79b
2%
MALT1
2%
GPR65
2%
TF
2%
BRAF
2%
CRAF
2%
MEK
2%
RAF
2%
ENPP1
2%
CD93
2%
gp100
2%
AXL
2%
HIF2a
2%
KIT
2%
RET
2%
ROS1
2%
VEGFR
2%
VEGFR2
2%
CLDN18.2
2%
CLDN6
2%
MAGE-A3
2%
MAGE-A4
2%
MAGE-C1
2%
PRAME
2%
IL-2
2%
Facility
2031 - Randwick - Scientia Clinical Research Ltd (44)
2109 - North Ryde - Macquarie University Hospital (14)
3168 - Clayton - Monash Medical Centre (14)
6009 - Nedlands - Linear Clinical Research (13)
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (7)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (7)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (6)
3199 - Frankston - Peninsula Health Frankston Hospital (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
4120 - Greenslopes - Greenslopes Private Hospital (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
2170 - Liverpool - Liverpool Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (3)
5000 - Adelaide - Cancer Research SA (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
2500 - Wollongong - Cancer Care Wollongong (2)
NA
4999 - Unspecified - Clinical Trial Site QLD (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
6009 - Nedlands - One Clinical Research (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
4215 - Southport - Gold Coast Private Hospital (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
6000 - Perth - Royal Perth Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
5999 - Unspecified - Clinical Trial Site WA (1)
4215 - Southport - Tasman Oncology (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
4812 - Townsville - Townsville University Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2170 - Liverpool - Sydney South West Private Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Upper gastrointestinal cancer
Gynaecological cancer
Urogenital cancer
Breast cancer
Pancreatobiliary cancer
Endometrial cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
HER2-positive solid tumour
Colorectal adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Male genital cancers
Prostate cancer
Ovarian cancer
Biliary tract cancer
Hepatobiliary cancer
HER2-expressing solid tumour
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
HPV-related cancer
Viral-related cancer
Breast adenocarcinoma
Melanoma
Clear cell renal cell carcinoma
Kidney cancer
Castrate-resistant prostate cancer
Haematological malignancy
Leukaemia
Lymphoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Prostate adenocarcinoma
HER2-negative breast cancer
HER2-positive breast cancer
RAS-mutant colorectal cancer
Central nervous system cancer
Glioma
Neurological cancer
Acral lentiginous melanoma
Biomarker-defined solid tumour
Bladder cancer
Cervical cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mesothelioma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy